Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis

Indian Journal of Nephrology

Volumn 21, Issue 4, 2011, Pages 245-249

  Vasantha, J ^a   Soundararajan, P ^a   Vanitharani, N ^a   Kannan, G ^a   Thennarasu, P ^a   Neenu, G ^a   Reddy, C ^a  

^a SRI RAMACHANDRA UNIVERSITY   (India)

Author keywords

Hemodialysis; Hyperphosphatemia; Nicotinamide; Phosphate; Renal disease

Indexed keywords

CALCIUM ACETATE; CALCIUM CARBONATE; FOSEAL; LANTHANUM CARBONATE; LANTHONATE; NIALIP; NICOTINAMIDE; PHOSPHATE BINDING AGENT; SEVELAMER; SHELCAL; UNCLASSIFIED DRUG;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FAILURE; LIQUID FECES; MALE; PHOSPHATE BLOOD LEVEL; TREATMENT DURATION;

EID: 80054013216     PISSN: 09714065     EISSN: 19983662     Source Type: Journal    
DOI: 10.4103/0971-4065.83735     Document Type: Article

References (40)

1. Melamed ML, Eutace JA, Plantinga L. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal study. Kidney Int 2006;70:351-7. (Pubitemid 44086585)
2. Block GA, Port FK. Re-evaluation of risk associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 2000;35:1226-37. (Pubitemid 30354431)
3. Block GA, Hulbert Shearon TE, Levin NW. Association of serum phosphorus and calcium-phosphate product with mortality risk in chronic hemodialysis patients: A National study. Am J Kidney Dis 1998;31:607-17.
4. Taylor AJ, Burke AP, O'Malley PG, Farb A, Malcom GT, Smialek J, et al. A comparison of the Framingham risk index, coronary artery calcification and culprit plaque morphology in sudden cardiac death. Circulation 2000;101:1243-48. (Pubitemid 30158610)
5. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18. (Pubitemid 39031360)
6. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, et al. Survival predictability of timevarying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771-80. (Pubitemid 44215354)
7. Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, Rodriguez M, Aljama P. Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis 2005;46:68-77. (Pubitemid 40848434)
8. National Kidney Foundation. K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1-S202.
9. Kuhlmann MK. Management of hyperphosphataemia. Hemodial Int 2006;10:338-45.
10. Manns B, Stevens L, Miskulin D, Owen WF Jr, Winkelmayer WC, Tonelli M. A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 2004;66:1239-47. (Pubitemid 39121034)
11. Wills, Savory J. Aluminium poisoning: Dialysis encephalopathy, osteomalacia and anemia. Lancet 1983;2:29-34.
12. Borràs M, Marco MP, Fernández E. Treatment with sevelamer decreases bicarbonate levels in peritoneal dialysis patients. Perit Dial Int 2002;22:737-8. (Pubitemid 36131512)
13. McIntyre CW, Patel V, Taylor GS, Fluck RJ. A prospective study of combination therapy for hyperphosphatemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients. Nephrol Dial Transplant 2002;17:1643-48. (Pubitemid 35012168)
14. Al-Baaj F, Speake M, Hutchison AJ. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Nephrol Dial Transplant 2006;20:775-82. (Pubitemid 40520656)
15. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, et al. Effect of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-42.
16. Asmus HG, Braun J, Krause R, Brunkhorst R, Holzer H, Schulz W. Two year comparison of sevelamer and calcium carbonate effect on cardiovascular calcification and bone density. Nephrol Dial Transplant 2005;20:1653-61. (Pubitemid 41418591)
17. Bogan KL, Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: A molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu Rev Nutr 2008; 28:115-30.
18. Denisi D, Caverzasio J, Trechsel U, Bonjour JP, Straub RW. Phosphate transport adaptation in rat jejunum and plasma level of 1,25-dihydroxyvitamin D3. Scand J Gastroenterol 1990;25:210-5. (Pubitemid 20194851)
19. Katai K, Tanaka H, Tatsumi S. Nicotinamide inhibits sodium dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 1999;14:1195-201. (Pubitemid 29209307)
20. Kempson SA, Colon-Otero G, Ou SY, Turner ST, Dousa TP. Possible role of nicotinamide adenine dinucleotide as an intracellular regulator of renal transport of phosphate in the rat. J Clin Invest 1981;67:1347-60. (Pubitemid 11099349)
21. Eto N, Miyata Y, Ohno H, Yamashita T. Nicotinamide prevents the development of hyperphosphatemia by suppressing intestinal sodium-dependent phosphate transporter in rats with a denininduced renal failure. Nephrol Dial Transplant 2005;20:1378-84. (Pubitemid 41430611)
22. Berndt TJ, Pfeifer JD, Knox FG, Kempson SA, Dousa TP. Nicotinamide restores phosphaturic effect of PTH and calcitonin in phosphate deprivation. Am J Physiol 1982; 242:F447-52. (Pubitemid 12099168)
23. Morrow JD, Parsons WG, Roberts LJ. Release of markedly increased quanitites of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins. 1989;38:263-74. (Pubitemid 19206949)
24. Meyers CD, Liu P, Kamanna VS, Kashyap ML. Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: An in vitro model of the niacin flush. Atherosclerosis 2007;192: 253-8. (Pubitemid 46726325)
25. Lorenzen A, Stannck C, Lang H, Andrianov V, Kalvinsh I, Schwabe U. Characterization of a G protein-coupled receptor for nicotinic acid. Mol Pharmacol 2001;59:349-357. (Pubitemid 32108569)
26. Wise A, Ford S, Fraser N. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003; 278:9869-74. (Pubitemid 36800490)
27. Anonymous. Vitamin b complex niacin American hospital formulary service drug information. Bethesda: American society of hospital pharmacist;1985.p.1685- 87.
28. Anonymous. Nicotinic acid, nicotinamide. In: Reynolds JE (ed). Martindale: The extra pharmacopoeia (30th ed), London: Pharmaceutical Press;1993.P.1045-46.
29. Bingley PJ, Mahon JL, Gale EA. European Nicotinamide Diabetes Intervention Trial Group. Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetes Care 2008;31:146-50.
30. Mohler H, Polc P, Cumin R, Pieri L, Ketter R. Nicotinamide is a brain constituent with benzodiazepine like actions. Nature 1979;278:563-5. (Pubitemid 9142690)
31. Bold JM, Gardner CR, Walker RJ. Central effects of niacinamide and inosine which are not mediated through benzodiazepine receptors. Br J Pharmac. 1985;84:689-96. (Pubitemid 15029913)
32. Miesel R, Kurpisz M, Kroger H. Modulation of inflammatory arthritis by inhibition of poly (ADP ribose) polymerase. Inflammation 1995;19:379-87.
33. Pero RW, Axelsson B, Siemann D, Chaplin D, Dougherty G. Newly discovered anti-inflammatory properties of the benzamides and nicotinamides. Mol Cell Biochem 1999;193:119-123.
34. Ungerstedt JS, Blomback M, Soderstrom T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol 2003;131:48-52. (Pubitemid 36098821)
35. Knip M, DOUEK I F, Moore WPT, Gillmor HA, Mclean M. Safety of high dose of nicotinamide: A review. Diabetologia 2000;43:1337-45.
36. Marcus R, Coulston AM. Water soluble vitamins. The vitamin B complex and ascorbic acid. In: Goodman-Gilman, editor. The pharmacological basis of therapeutics. 9th ed, Newyork: Mc grawhill; 1996.p.1555-71.
37. Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1131-38.
38. Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T, Shibata k, Shimada N. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 2004;65:1099-104. (Pubitemid 38251086)
39. Sampathkumar K, Selvam M, Sooraj YS, Gowthaman S, Ajeshkumar RN. Extended release nicotinic acid - a novel oral agent for phosphate control. Int Urol Nephrol 2006;38(1):171-4.
40. Muller D, Mehling H, Otto B, Bergmann-Lips R, Luft F, Jordan J, et al. Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients. Clin J Am Soc Nephrol 2007;2:1249-54.